glp-1/gcgr dual agonist GCGR: A Key Target in Glucose Metabolism-DIMA BIOTECH Targeting GLP-1, GIP & GCG
Description
doi: 10.1016/j.peptides.2017.11.017
This glucose-dependent mechanism reduces hypoglycemia risk compared to insulin or sulfonylureas
Patients are typically instructed by their clinician or dispensing pharmacy on how to prepare and administer each dose
2012;303:E25364
Lilly has submitted orforglipron for approval in more than 40 countries, with launches expected in each market following regulatory clearance
